Myocardial damage as a result of implantation and defibrillation testing in transvenous and subcutaneous implantable cardioverter-defibrillators.

17 March 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Rapid Fire 4: The shocking truth of device therapy Implantable Cardioverter-Defibrillator (ICD) EHRA Premium Access EHRA 2019

ESC 365 is supported by

ESC 365 is supported by